MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[31] Extracellular Vesicles: A New Nano Tool for the Treatment of Inflammatory Bowel Diseases
Tandra, Nitin
Wu, Peipei
Hu, Xinyuan
Mao, Fei
Xu, Wenrong
Qian, Hui
CURRENT NANOSCIENCE, 2019, 15 (06) : 589 - 595
[32] New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
D'Amico, Ferdinando
Peyrin-Biroulet, Laurent
Danese, Silvio
Fiorino, Gionata
CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 141 - 150
[33] DNA therapeutics: a feasible option for treatment of inflammatory diseases?
Wagner, E.
ARTHRITIS RESEARCH & THERAPY, 2001, 3 (Suppl 2)
[34] DNA therapeutics: a feasible option for treatment of inflammatory diseases?
E Wagner
Arthritis Research & Therapy, 3
[35] The Efficacy of Mirikizumab in Inflammatory Bowel Disease: A Meta-Analysis
Chaudhary, Muhammad Y. N.
Jawwad, Mohammad
Ismail, Muhammad
Chaudhary, Muhammad H. N.
Naveed, Umna
Hasan, Fariha
Singh, Ajeet
Riaz, Monazza
Arham, Abdul
Serrano, Oluwagbenga
Basit, Syed Abdul
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1064 - S1065
[36] Diet in the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Lee, Dale
Albenberg, Lindsey
Compher, Charlene
Baldassano, Robert
Piccoli, David
Lewis, James D.
Wu, Gary D.
GASTROENTEROLOGY, 2015, 148 (06) : 1087 - 1106
[37] Treatment of chronic inflammatory bowel diseases - Discussion
Binet, M. Jacques-Louis
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (06): : 1141 - 1141
[38] CYCLOSPORINE-A TREATMENT IN INFLAMMATORY BOWEL DISEASES
BRAZIER, F
FINET, L
DUCHMANN, JC
DUPAS, JL
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1995, 19 (05): : 494 - 504
[39] The role of hypnotherapy for the treatment of inflammatory bowel diseases
Moser, Gabriele
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (06) : 601 - 606
[40] Personalized medicine in the treatment of inflammatory bowel diseases
Parfenov, A. I.
Knyazev, O. V.
Kagramanova, A. V.
Fadeeva, N. A.
TERAPEVTICHESKII ARKHIV, 2018, 90 (02) : 4 - 11

← 1 2 3 4 5 →